CALGARY, Alberta, Dec. 10, 2025 — Hemostemix Inc., a leader in autologous stem cell therapeutics, announced two pivotal corporate developments: the scheduling of its FDA Pre-IND meeting for January 16, 2026, to advance its basket trial protocol for ischemia-related conditions, and a planned non-brokered private placement (NBPP) of up to $960,000. These developments mark a significant step in the Company’s strategy to commercialize ACP-01, its proprietary VesCell™ therapy for vascular dementia, cardiomyopathy, peripheral arterial disease, and chronic limb-threatening ischemia.
Science Significance
Hemostemix’s autologous stem cell platform has demonstrated encouraging outcomes across seven clinical studies involving 318 subjects, with eleven peer-reviewed publications supporting ACP-01’s safety and clinical relevance. The newly presented basket protocol integrates multiple ischemia-driven diseases under a unified mechanism of action, reflecting a scientific understanding that conditions such as vascular dementia, ischemic cardiomyopathy, PAD, and generalized ischemia share underlying pathophysiology related to impaired blood flow. ACP-01’s Angiogenic Cell Precursors aim to regenerate compromised vasculature, improve cardiac function, accelerate wound healing, and reduce pain, providing a scientifically grounded rationale for a multi-indication clinical strategy.
Regulatory Significance
The scheduled FDA Pre-IND meeting represents a significant regulatory inflection point for Hemostemix as the Company prepares for its Phase I basket trial. The meeting will address clinical rationale, manufacturing processes, and pathway considerations essential for U.S. regulatory advancement. The Company’s emphasis on a Phase I design echoes precedent—such as other cell therapies gaining clearance based on early-phase evidence—while enabling a structure in which patients may be treated and followed under regulated investigation. This milestone strengthens Hemostemix’s positioning within the U.S. framework for regenerative medicine and supports a coherent strategy for bringing ACP-01 toward formal approval.
Business Significance
Advertisement
The proposed $960,000 private placement enhances Hemostemix’s financial readiness to execute regulatory preparations, expand clinical operations across Florida, The Bahamas, and Canada, and support general corporate activities. As CEO Thomas Smeenk noted, the basket trial could streamline clinical development and broaden ACP-01’s commercial viability by aligning multiple revenue-generating treatment indications under a unified protocol. The financing structure—8,000,000 shares at $0.12 with no warrants—positions the Company for near-term operational continuity while reinforcing investor confidence in the ACP-01 platform’s expanding market potential.
Patients’ Significance
For patients with severe ischemia-related diseases, the ACP-01 platform offers a potential alternative where standard therapies often fail. Clinical data from prior studies reported wound healing in 83% of chronic limb-threatening ischemia patients, cessation of pain, improved cardiac function, and enhanced quality of life. ACP-01’s autologous nature reduces risks associated with immune rejection while aiming to restore natural vascular function. The planned basket trial could significantly accelerate access for individuals with vascular dementia, cardiomyopathies, PAD, and ischemic pain, offering the possibility of a regenerative solution where treatment gaps remain substantial.
Policy Significance
The Company’s regulatory trajectory intersects with broader healthcare policy trends supporting innovative regenerative technologies, patient-funded treatment models, and expanded early-phase clinical pathways. In jurisdictions like Florida, where compassionate use and alternative cell therapy frameworks are evolving, Hemostemix’s ACP-01 may benefit from emerging policy structures that encourage controlled access to investigational therapies. As governments increasingly focus on outcomes-driven evaluation and accessibility for chronic ischemic conditions, Hemostemix’s clinical and regulatory progress aligns with policy priorities emphasizing innovation, patient autonomy, and evidence-based deployment of advanced biologics.
Hemostemix’s FDA Pre-IND scheduling and planned private placement collectively underscore its momentum toward bringing ACP-01 into the U.S. clinical development landscape. With a unified ischemia-based scientific strategy, expanding operational footprint, and strong clinical data foundation, the Company is positioning ACP-01 as a potentially transformative therapy for multiple high-burden conditions. As regulatory discussions advance in early 2026, Hemostemix continues building a framework aimed at delivering scalable, patient-centered regenerative solutions to global ischemia-related disease populations.
Source: Hemostemix press release
